Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

licencing

- PMLiVE

Leo Pharma plans to share trial data from 2014

"It is the right thing to do" says UK managing director

- PMLiVE

AstraZeneca to close UK environmental lab

Decision on Brixham facility in Devon puts 71 positions at risk

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

AZ buys into ADC sector with $440m Spirogen deal

Pushes into the market for antibody-drug conjugates

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

Xeljanz effective in psoriasis says Pfizer

Data backs extension of drug’s indications

- PMLiVE

AstraZeneca advertises Crestor with ‘fun’ TV spot

TV campaign compares choice of medicine over Lipitor to sporting rivalry

- PMLiVE

AZ/Amgen report positive data with psoriasis antibody

Brodalumab shows efficacy in achieving and maintaining clear skin

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

New arrivals join BioHub at AZ’s Alderley Park

Six new biopharma start-ups set up at the UK biocluster

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links